SSR150106

SSR150106 is an investigational small molecule drug developed by Sanofi as an oral anti-inflammatory agent. It acts primarily as a C-C chemokine receptor type 2 (CCR2) antagonist and tumor necrosis factor-alpha (TNFα) inhibitor. The compound was studied for its potential to reduce inflammation in immune-mediated diseases, with clinical trials conducted in patients with active rheumatoid arthritis. Its mechanism of action involves blocking the CCR2 receptor, which plays a key role in monocyte recruitment and inflammatory signaling, as well as inhibiting TNFα activity. Development reached phase II clinical trials for rheumatoid arthritis and postoperative pain but was subsequently discontinued[1][2][3][5].

Other names

UNII-5WX0OAF07IUNII5WX0OAF07IUNII 5WX0OAF07IIsoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-